* Regents delay decision on creation of athletics committee
   
* Regents exploring professional development for educators
   
* Three faculty members earn Distinguished Professor title
   
* New cohort of teaching researchers begins year's mission
   
* Student enrollment strong on all CU campuses
   
* CU-Boulder reaccredited for another decade
   
* CU community encouraged to 'Live Free' during sobriety challenge
   
* Five questions for Sean Colgan
   
* People
   
* Did you know...
   
* Letters to the editor
 
 NEWS FROM THE CU SYSTEM
 
  CU-BOULDER
  Dedication of complex, opening of museum highlight Arts and Culture Week
 
  UCCS
  Concrete sign to be a solid reminder of campus territory
 
  UC DENVER
  STEMapalooza to stimulate young minds
 
  ANSCHUTZ MEDICAL CAMPUS
  Colorado School of Public Health wins $3.2 million grant
 
  TECH TRANSFER
  Aurora company licenses CU technology for brain disease treatment
 
   Home
   Newsletter Archive
 
Download Newsleter in PDF
 
  LETTERS TO THE EDITOR
Share your opinions

CONTACT US
Send your thoughts and suggestions
   
   
   
   
   
   

News from the CU system - Tech Transfer

Aurora company licenses CU technology for brain disease treatment

The University of Colorado and Aurora-based ICVrx recently completed a license agreement allowing the company to commercialize CU technology for improved treatment of epilepsy and other neurological disorders.

Many of the most effective oral medicines for neurological diseases are toxic to the body; although these medicines are nontoxic to the brain, getting the drug into the central nervous system without causing dangerous side effects in the body is a challenge. What's more, many patients with neurological disorders do not adhere to the prescribed dosing regimen; this is especially relevant in patients with mental illnesses like schizophrenia.

The licensed technology is a drug reformulation technique that allows these drugs to be administered directly into the fluid around the brain via an implantable pump. This technique enables significantly lower dosages (reducing side effects and toxicity) and also can help overcome patient compliance problems.

The technology was developed by Daniel J. Abrams and Karen Stevens, both of the CU School of Medicine department of psychiatry, and Thomas Anchordoquy of the department of pharmaceutical sciences.

ICVrx was founded in 2009 to commercialize this technology; the company is currently focusing on treatment of "refractory epilepsy" – epilepsy that has proven difficult or impossible to control using standard drug treatments. For this group of patients (600,000 in the U.S.), driving and other essential daily activities might be impossible due to uncontrolled or poorly controlled seizures.

"Although these patients may appear to their neighbors to be normal, they have a very poor quality of life and high need," said Abrams, who also is ICVrx's CEO. "Currently there are only two treatment options – brain surgery to remove part of the brain, or an implanted device called a Vagus Nerve Stimulator, which has risks, is irreversible and has limited effectiveness. Only 10 percent of patients pursue either."

The company has completed preclinical work on three potential drug therapies in preparation for clinical trials, which it hopes to begin in 2011.

"The ICVrx technology would address an important and unmet therapeutic need for the target patient populations, and we wish the company every success in bringing this to market," said Tom Smerdon, director of licensing and new business development at the CU Technology Transfer Office.

Bookmark - Print - Share

 
Previous Tech Transfer Stories

09/15/2010
Boulder company to commercialize CU hybrid aircraft propulsion technology

07/14/2010
Aurora company licenses unusual approach to treating inflammatory disease

06/30/2010
Optioned device helps diagnose acid reflux, other esophageal diseases

06/16/2010
Taste Connections licenses CU low-protein meat supplement

05/26/2010
White House turns to CU for input on technology commercialization

05/05/2010
Biotech company expands Alzheimer's disease partnership with CU

04/21/2010
Sanofi Pasteur licenses E. coli vaccine technology

04/07/2010
CU ranked 14th among universities in 'Patent Power'

03/31/2010
CU cardiovascular monitoring technology to be commercialized

03/10/2010
Israel-based company licenses water desalination technology

03/03/2010
Colorado company licenses CU test to assess chronic liver disease

01/20/2010
AgriHouse completes license for CU water management technology

01/13/2010
AmideBio licenses technology from CU

01/06/2009
Business collaboration leads to high ranking for CU-Boulder

12/16/2009
License agreement gives Viral Genetics Inc. right to develop cancer therapies

12/09/2009
Soligenix options CU vaccine technology

12/02/2009
Aurora company licenses CU technology for 3-D heart modeling

09/23/2009
Colorado firm aims to commercialize CU breakthroughs in pain management

09/16/2009
Office reports best year for invention disclosures

09/16/2009
Office invites bioscience faculty to submit grant proposals

09/02/2009
Reading software based on CU technology draws national attention

08/19/2009
CU startup to develop 'biogenerator' for medical devices

08/06/2009
CU startup licenses social networking iPhone app